The Propionic Acidemia Market Size shall grow during the forecast period owing to the expected launch of novel emerging therapies, which shall fuel the growth of the market during the forecast period, i.e., 2020–2030.
Propionic acidemia (PA) is a rare inborn errors of metabolism that can cause early mortality and significant morbidity. In the base case, LT on average resulted in 1.5 more life years lived, 7.9 more quality-adjusted life years (QALYs), and a savings of $582,369 for lifetime societal cost per individual compared to nutritional support.
LT remained more effective and less costly in all 1-way sensitivity analyses. Moreover, in the probabilistic sensitivity analysis, LT was cost-effective at the $100,000/QALY threshold and was likely a dominant treatment strategy compared to nutritional support in newborns with PA.
Dietary management with medical foods had been a mainstay of therapy for decades, yet well controlled patients can manifest growth, development, cardiac, ophthalmological, renal, and neurological complications. Additionally, Liver transplantation improved overall metabolic control, but injury to nonregenerative tissues might not be mitigated. However, continued use of medical foods in these patients requires prospective studies to demonstrate evidence of benefit in a controlled manner.
Research is underway to identify novel treatment approaches that may address some of the challenges to existing treatment. Key players, such as Moderna Tx (mRNA-3927), HemoShear (HST5040) etc., are involved in developing therapies for the treatment of Propionic Acidemia.
DelveInsight's "Propionic Acidemia - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Propionic Acidemia, historical and forecasted epidemiology as well as the Propionic Acidemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Propionic Acidemia market report provides current treatment practices, emerging drugs, Propionic Acidemia market share of the individual therapies, current and forecasted Propionic Acidemia market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Propionic Acidemia treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
It covers the details of conventional and current medical therapies available in the Propionic Acidemia market for the treatment of the condition. It also provides Propionic Acidemia treatment algorithms and guidelines in the United States, Europe, and Japan. The Propionic Acidemia epidemiology division provide insights about historical and current Propionic Acidemia patient pool and forecasted trend for every seven major countries.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides th
e diagnosed patient pool and their trends along with assumptions undertaken.
Drug chapter segment of the Propionic Acidemia report encloses the detailed analysis of Propionic Acidemia marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Propionic Acidemia clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Comments